With King in its fold, Pfizer -- which makes Lyrica and Celebrex -- believes it can build an industry-leading portfolio of pain relievers. Among King's most appealing entrants in that market is the new Embeda, designed to prevent misuse and abuse.
The stock of the world's largest drugmaker has been a laggard lately. But that could be soon changing if analysts who are pointing to a solid lineup of new products are right. They think the giant can easily offset the patent loss for Lipitor.